BioMarin Pharmaceutical Inc.
BMRN
$62.28
-$5.20-7.71%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 17.78% | -1.02% | 20.88% | 335.15% | -49.54% |
| Total Depreciation and Amortization | 24.21% | -28.18% | -3.24% | 1.82% | 4.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 109.70% | 10.16% | 43.20% | -53.02% | 160.80% |
| Change in Net Operating Assets | -312.87% | 158.37% | 36.50% | -8.52% | -343.28% |
| Cash from Operations | -16.19% | 86.49% | 152.84% | 70.91% | -79.74% |
| Capital Expenditure | -5.78% | 13.43% | 18.30% | 9.73% | -33.04% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4,060.19% | -97.94% | 842.09% | 132.92% | -49.79% |
| Cash from Investing | 572.88% | -117.86% | 735.57% | 78.09% | -41.84% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -2,749,494.44% | 57.14% | -- | -- |
| Issuance of Common Stock | 63.89% | -83.70% | 308.80% | -51.39% | 239.95% |
| Repurchase of Common Stock | 16.97% | 64.79% | 66.38% | -1,174.18% | 13.60% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 96.95% | -- | -- | -- | 97.99% |
| Cash from Financing | 100.57% | -4,057.54% | 129.47% | -494.77% | 1,475.63% |
| Foreign Exchange rate Adjustments | 186.32% | -187.91% | 71.25% | 152.84% | -284.75% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 190.12% | -231.78% | 2,869.08% | 73.15% | -133.27% |
